Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RISPERIDONE vs ABILIFY MYCITE KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
Schizophrenia,Bipolar I disorder (acute manic or mixed episodes),Irritability associated with autistic disorder,Adjunctive therapy in major depressive disorder,Tourette syndrome (off-label),Obsessive-compulsive disorder (off-label)
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
Risperidone: 3 hours (CYP2D6 extensive metabolizers), 20 hours (poor metabolizers); active metabolite 9-hydroxyrisperidone: 21-30 hours; steady-state reached in 5-6 days
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Extensively metabolized in the liver via CYP2D6 and CYP3A4 to 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. The parent drug and metabolite are equally active.
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Renal (70% as metabolites, 14% as parent drug) and fecal (14%)
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Risperidone: 90% bound to albumin and alpha-1-acid glycoprotein; 9-hydroxyrisperidone: 77% bound
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
Risperidone: 1-2 L/kg; 9-hydroxyrisperidone: 0.5-1 L/kg; extensive tissue distribution
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
Oral: 70% (tablet), 70% (oral solution); intramuscular: 100% for immediate-release, 28% for long-acting injection relative to oral
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
Cr Cl ≥30 m L/min: no adjustment. Cr Cl <30 m L/min: initiate at 0.5 mg orally twice daily for at least 1 week, then increase by 0.5 mg twice daily as tolerated; maximum 3 mg/day.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
Child-Pugh Class A or B: initiate at 0.5 mg orally twice daily, increase cautiously. Class C: avoid or use with extreme caution; no specific established dose.
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Adolescents (13-17 yr) with schizophrenia: initial 0.5 mg orally once daily, titrate to 3 mg/day as tolerated. Children (10-17 yr) with bipolar mania: initial 0.5 mg once daily, titrate to 1-2.5 mg/day. Weight-based not standard; use fixed dosing.
Not approved for patients <18 years; safety and effectiveness not established.
Initiate at 0.5 mg orally once daily; increase by 0.5 mg/day increments; target dose 1-2 mg/day; monitor for orthostasis and extrapyramidal symptoms.
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events (stroke, TIA) in elderly with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Weight gain,Hyperprolactinemia,Orthostatic hypotension,Seizures,Leukopenia/neutropenia/agranulocytosis,QT interval prolongation,Priapism,Dysphagia,Body temperature dysregulation,Potential for cognitive and motor impairment
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
Hypersensitivity to risperidone or any component of the formulation
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Avoid grapefruit and grapefruit juice; may increase risperidone plasma concentrations. Alcohol can potentiate CNS depression and increase risk of side effects. No specific food restrictions; take with or without food. High-fat meals may slightly increase absorption.
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposure may cause neonatal extrapyramidal symptoms (e.g., agitation, hypertonia, tremors) and withdrawal symptoms (e.g., respiratory distress, feeding difficulties).
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
Risperidone is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5 for the parent drug and 0.3 for the active moiety (risperidone + 9-hydroxyrisperidone). Relative infant dose (RID) is about 2-4% of the maternal weight-adjusted dose. Monitor the infant for sedation, poor feeding, and extrapyramidal effects. The benefit of breastfeeding should be weighed against potential risks.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
Increased clearance of risperidone in pregnancy may require dose adjustments. Some studies suggest a dose increase of 20-30% during the second and third trimesters to maintain therapeutic levels. TDM is recommended to guide dosing, with target trough concentrations similar to non-pregnant patients (10-20 ng/m L for the active moiety). Postpartum dose should be reduced to pre-pregnancy levels.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
Monitor for orthostatic hypotension, especially during dose titration. Risperidone can cause QTc prolongation; obtain baseline ECG in at-risk patients. Extrapyramidal symptoms (EPS) are dose-dependent; use lowest effective dose. In elderly dementia patients, increased risk of cerebrovascular events; not approved for this indication. Prolactin elevation is common; monitor for gynecomastia, galactorrhea, and sexual dysfunction. Taper slowly to avoid withdrawal dyskinesia.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
Take risperidone exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol and grapefruit juice as they may affect drug levels and increase side effects.,Rise slowly from sitting or lying down to prevent dizziness from low blood pressure.,Report any involuntary muscle movements, restlessness, or stiffness to your healthcare provider.,Notify your doctor if you experience breast swelling, discharge, or sexual problems.,Do not drive or operate heavy machinery until you know how risperidone affects you.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
"Carvedilol, a nonselective beta-blocker with alpha1-blocking activity, may enhance the hypotensive effects of risperidone, an atypical antipsychotic with alpha1-adrenergic antagonism. This additive pharmacodynamic interaction can lead to exaggerated blood pressure reduction, orthostatic hypotension, dizziness, and increased risk of syncope, particularly during initial dosing or dose titration. Patients with cardiovascular comorbidity or volume depletion are at heightened risk for adverse outcomes such as falls or cardiac ischemia."
"Cilazapril, an angiotensin-converting enzyme inhibitor (ACEI), reduces angiotensin II production and aldosterone secretion, leading to vasodilation and decreased blood pressure. Risperidone, an atypical antipsychotic, can cause orthostatic hypotension through alpha-1 adrenergic receptor blockade. Concurrent use may result in additive hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope, particularly at treatment initiation or dose adjustments."
"Coadministration of risperidone and pizotifen may lead to additive anticholinergic and sedative effects due to their overlapping pharmacological profiles. Risperidone, an atypical antipsychotic with histamine H1 receptor antagonist properties, combined with pizotifen, a serotonin antagonist with strong anticholinergic and antihistaminergic activity, can result in excessive sedation, cognitive impairment, and peripheral anticholinergic effects such as dry mouth, constipation, and urinary retention. Clinically, this interaction increases the risk of falls, confusion, and reduced functional status, especially in elderly patients or those with pre-existing central nervous system depression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RISPERIDONE vs ABILIFY MYCITE KIT, answered by our medical review team.
RISPERIDONE is a Atypical Antipsychotic that works by Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. It also has moderate affinity for alpha1-adrenergic and H1-histaminergic receptors, and low affinity for muscarinic receptors.. ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RISPERIDONE and ABILIFY MYCITE KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RISPERIDONE is: Initial 2 mg orally once daily, titrated to target dose of 4-6 mg orally once daily (or divided twice daily); maximum 16 mg/day. Alternatively, long-acting IM injection: 25 mg IM every 2 weeks.. The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RISPERIDONE and ABILIFY MYCITE KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RISPERIDONE is classified as Category A/B. Risperidone is not a major teratogen in humans based on available studies, but there is a slight increase in risk for gestational diabetes and preterm birth. Third-trimester exposu. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.